» Articles » PMID: 27737892

Activity of Nonmuscle Myosin II Isoforms Determines Localization at the Cleavage Furrow of Megakaryocytes

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2016 Oct 15
PMID 27737892
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Megakaryocyte polyploidy is characterized by cytokinesis failure resulting from defects in contractile forces at the cleavage furrow. Although immature megakaryocytes express 2 nonmuscle myosin II isoforms (MYH9 [NMIIA] and MYH10 [NMIIB]), only NMIIB localizes at the cleavage furrow, and its subsequent absence contributes to polyploidy. In this study, we tried to understand why the abundant NMIIA does not localize at the furrow by focusing on the RhoA/ROCK pathway that has a low activity in polyploid megakaryocytes. We observed that under low RhoA activity, NMII isoforms presented different activity that determined their localization. Inhibition of RhoA/ROCK signaling abolished the localization of NMIIB, whereas constitutively active RhoA induced NMIIA at the cleavage furrow. Thus, although high RhoA activity favored the localization of both the isoforms, only NMIIB could localize at the furrow at low RhoA activity. This was further confirmed in erythroblasts that have a higher basal RhoA activity than megakaryocytes and express both NMIIA and NMIIB at the cleavage furrow. Decreased RhoA activity in erythroblasts abolished localization of NMIIA but not of NMIIB from the furrow. This differential localization was related to differences in actin turnover. Megakaryocytes had a higher actin turnover compared with erythroblasts. Strikingly, inhibition of actin polymerization was found to be sufficient to recapitulate the effects of inhibition of RhoA/ROCK pathway on NMII isoform localization; thus, cytokinesis failure in megakaryocytes is the consequence of both the absence of NMIIB and a low RhoA activity that impairs NMIIA localization at the cleavage furrow through increased actin turnover.

Citing Articles

CircSP3 encodes SP3-461aa to promote ccRCC progression via stabilizing MYH9 and activating the PI3K-Akt signaling pathway.

Wu X, Sun G, Fan R, Liu K, Duan C, Mao X J Cancer. 2024; 15(18):5876-5896.

PMID: 39440063 PMC: 11493002. DOI: 10.7150/jca.100706.


-related inherited thrombocytopenia: the genetic spectrum, underlying mechanisms, clinical phenotypes, diagnosis, and management approaches.

Shen K, Chen T, Xiao M Res Pract Thromb Haemost. 2024; 8(6):102552.

PMID: 39309229 PMC: 11415342. DOI: 10.1016/j.rpth.2024.102552.


A pre-B acute lymphoblastic leukemia cell line model reveals the mechanism of thalidomide therapy-related B-cell leukemogenesis.

Ramani M, Singh R, Shrivastva S, Ribeyron L, Gupta S, Roy A J Biol Chem. 2024; 300(8):107578.

PMID: 39029626 PMC: 11367411. DOI: 10.1016/j.jbc.2024.107578.


Synaptopodin stress fiber and contractomere at the epithelial junction.

Morris T, Sue E, Geniesse C, Brieher W, Tang V J Cell Biol. 2022; 221(5).

PMID: 35416930 PMC: 9011326. DOI: 10.1083/jcb.202011162.


Macrothrombocytopenia of Takenouchi-Kosaki syndrome is ameliorated by CDC42 specific- and lipidation inhibitors in MEG-01 cells.

Daimon E, Shibukawa Y, Thanasegaran S, Yamazaki N, Okamoto N Sci Rep. 2021; 11(1):17990.

PMID: 34504210 PMC: 8429552. DOI: 10.1038/s41598-021-97478-y.